Double-Punch immunotherapy trial aims to tame aggressive blood cancer

This study is testing whether using two newer immunotherapy drugs (teclistamab and talquetamab) at different times during treatment can help people with high-risk multiple myeloma live longer without their cancer progressing. It will enroll 50 adults with newly diagnosed, aggressive forms of this blood cancer. The treatment plan is personalized: some participants will receive a stem cell transplant, while others will skip it based on highly sensitive tests that detect tiny amounts of remaining cancer cells.